Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

被引：0
|
作者：
Fuchs, Charles S.
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun Cheol
Muro, Kei
Van Cutsem, Eric
Elme, Anneli
Thuss-Patience, Peter C.
Chau, Ian
Ohtsu, Atsushi
Bhagia, Pooja
Wang, Anran
Shih, Chie-Schin
Shitara, Kohei
机构：
[1] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[2] Istanbul Univ, Cerrahpasa Cerrahpasa Med Fac, Istanbul, Turkey
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[5] ASST Papa Giovanni XXIII, Bergamo, Italy
[6] Asan Med Ctr, Seoul, South Korea
[7] Azienda Osped Univ Pisana, Pisa, Italy
[8] Maria SkLodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[9] Inst Oncol Fdn Arturo Lopez Perez, Santiago, Chile
[10] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Leuven Canc Inst, Leuven, Belgium
[13] Sa Pohja Eesti Regionaalhaigla, Tallinn, Estonia
[14] Charite Univ Med Berlin, Campus Virchow Klinikum, Berlin, Germany
[15] Royal Marsden Hosp NHS Fdn Trust, London, England
[16] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[17] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4503
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    [J]. GASTRIC CANCER, 2022, 25 (01) : 197 - 206
  • [2] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Charles S. Fuchs
    Mustafa Özgüroğlu
    Yung-Jue Bang
    Maria Di Bartolomeo
    Mario Mandala
    Min-Hee Ryu
    Lorenzo Fornaro
    Tomasz Olesinski
    Christian Caglevic
    Hyun C. Chung
    Kei Muro
    Eric Van Cutsem
    Anneli Elme
    Peter Thuss-Patience
    Ian Chau
    Atsushi Ohtsu
    Pooja Bhagia
    Anran Wang
    Chie-Schin Shih
    Kohei Shitara
    [J]. Gastric Cancer, 2022, 25 : 197 - 206
  • [3] KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer
    Shitara, Kohei
    Muro, Kei
    Satoh, Taroh
    Tamura, Takao
    Chin, Keisho
    Machida, Nozomu
    Hara, Hiroki
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Mayo, Carlos
    Han, Rong
    Shiratori, Shinichi
    Ohtsu, Atsushi
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 49 - 49
  • [4] Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Kang, S. Peter
    Mayo, Carlos Alberto
    Ohtsu, Atsushi
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
    Shitara, K.
    Ozguroglu, M.
    Bang, Y. J.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M. H.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Gokkurt, E.
    Mansoor, W.
    McDermott, R.
    Schacham-Shmueli, E.
    Chen, X.
    Kang, S. P.
    Mayo, C.
    Ohtsu, A.
    Fuchs, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [6] Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1-positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.
    Chung, Hyun Cheol
    Kang, Yoon-Koo
    Chen, Zhendong
    Bai, Yuxian
    Ishak, Wan Zamaniah Wan
    Shim, Byoung Yong
    Park, Youngiee
    Koo, Dong-Hoe
    Lu, Jin Wei
    Xu, Jianming
    Bhagia, Pooja
    Kuang, Shu
    Shih, Chie-Schin
    Qin, Shukui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
    Shitara, Kohei
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Mayo, Carlos
    Kang, S. Peter
    Ohtsu, Atsushi
    Fuchs, Charles S.
    [J]. LANCET, 2018, 392 (10142): : 123 - 133
  • [8] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
    Wainberg, Zev A.
    Shitara, Kohei
    Van Cutsem, Eric
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol Cheol
    Lee, Jeeyun
    Castro-Salguero, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Goekkurt, Eray
    Satake, Hironaga
    Chao, Joseph
    Kher, Uma
    Shah, Sukrut
    Bhagia, Pooja
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Yoon, H.
    Fuchs, C.
    Ozguroglu, M.
    Bang, Y.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Van Cutsem, E.
    Elme, A.
    Thuss-Patience, P.
    Chau, I.
    Ohtsu, A.
    Wang, A.
    Bhagia, P.
    Lin, J.
    Shih, C.
    Shitara, K.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S236 - S236
12345